Publication Name	World Journal of Virology
Manuscript ID	88660
Country	Iran

Received	2023-10-04 06:35
Peer-Review Started	2023-10-04 06:37
To Make the First Decision
Return for Revision	2023-10-09 08:18
Revised	2023-11-09 19:41
Second Decision	2023-12-22 00:10
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-12-29 07:00
Articles in Press	2023-12-29 07:00
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-12-21 06:32
Typeset the Manuscript	2024-02-19 01:18
Publish the Manuscript Online	2024-03-11 14:44

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Meta-Analysis
Article Title	Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Behnam Amani, Lida Khodavirdilou, Kourosh Rajabkhah, Vida Kardan Moghaddam, Arash Akbarzadeh and Bahman Amani
Funding Agency and Grant Number
Corresponding Author	Bahman Amani, MSc, Researcher, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Qods Street, Keshavarz Blvd, Tehran 1416634793, Iran. b89amani@yahoo.com
Key Words	SARS-CoV-2; COVID-19; Bamlanivimab; Monoclonal antibody; Meta-analysis
Core Tip	The present study is the most comprehensive systematic review and meta-analysis on the efficacy and safety of bamlanivimab in the treatment of coronavirus disease 2019 (COVID-19). A significant difference was observed between the bamlanivimab and standard of care/placebo groups in terms of mortality rate, hospitalization rate, and emergency department visits. While the two groups exhibited no significant difference in terms of intensive care unit admission. The present results suggested that bamlanivimab might be effective and safe for the treatment of COVID-19.
Publish Date	2024-03-11 14:44
Citation	Amani B, Khodavirdilou L, Rajabkhah K, Kardan Moghaddam V, Akbarzadeh A, Amani B. Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis. World J Virol 2024; 13(1): 88660
URL	https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm
DOI	https://dx.doi.org/10.5501/wjv.v13.i1.88660

Full Article (PDF)	WJV-13-88660-with-cover.pdf
Full Article (Word)	WJV-13-88660.docx
PRISMA 2009 Checklist	88660-PRISMA 2009 Checklist.pdf
Manuscript File	88660_Auto_Edited-JJW-Filipodia-YJP.docx
Answering Reviewers	88660-Answering reviewers.pdf
Audio Core Tip	88660-Audio core tip.m4a
Biostatistics Review Certificate	88660-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	88660-Conflict-of-interest statement.pdf
Copyright License Agreement	88660-Copyright license agreement.pdf
Supplementary Material	88660-Supplementary material.pdf
Peer-review Report	88660-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	88660-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	88660-Bing-Wang JJ-2.png
Scientific Editor Work List	88660-Scientific editor work list.pdf
CrossCheck Report	88660-CrossCheck report.pdf